0001641489-23-000043.txt : 20230626 0001641489-23-000043.hdr.sgml : 20230626 20230626162432 ACCESSION NUMBER: 0001641489-23-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230621 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 231042658 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 8-K 1 vtvt-20230621.htm 8-K vtvt-20230621
FALSE0001641489NASDAQ00016414892023-06-212023-06-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported):  June 21, 2023
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37524
47-3916571
(State or other jurisdiction
of incorporation)
(Commission File No.)
(IRS Employer
Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.01 per shareVTVT
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing.
On June 21, 2023, vTv Therapeutics, Inc. (the “Company”) received a notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has determined the Company did not regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by June 20, 2023, the deadline to regain compliance with the Rule pursuant to the notice the Company received from Nasdaq on December 22, 2022 (the “Extension Notice”), and therefore the Company’s common stock will be delisted from The Nasdaq Capital Market. Nasdaq indicated that it will suspend trading in the Company’s common stock at the opening of business on June 30, 2023, and file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s common stock from listing and registration on Nasdaq, unless the Company requests a hearing to appeal Nasdaq’s delisting determination to a Hearings Panel (the “Panel”) no later than 4:00 pm ET on June 28, 2023 and such hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision.
On June 22, 2023, the Company submitted a request to Nasdaq for a hearing to appeal its delisting determination. In response to the Company’s request for a hearing, on June 22, 2023, the Company received a letter (the “Hearing Letter”) from Nasdaq stating that its delisting action has been stayed, pending a final decision by the Panel and a hearing will be held on August 17, 2023, at 9:00 a.m. via video conference. The Hearing Letter also provided the Company with the opportunity to participate in an expedited review process by completing a questionnaire regarding the Company’s compliance plan and returning it to the Panel no later than June 29, 2023. The Company will take such opportunity and submit the questionnaire to Nasdaq no later than June 29, 2023.
Based on its review of the Company’s responses to the questionnaire, the Panel may determine that an oral hearing is not necessary to grant the Company an exception to regain compliance in this matter. In this event, no hearing will be necessary and the Panel will issue a decision describing the terms of the exception, including the compliance deadline and any milestones the Company must meet, based on the Company’s responses to the questionnaire and the written record. If the Panel is unable to conclude that an exception is appropriate based on the Company’s responses to the questionnaire and the written record, there would be no prejudice against the Company and the hearing will proceed as scheduled.
The Company intends to submit a plan to regain compliance with the continued listing requirements to the Panel as part of the hearing process. There can be no assurance that Nasdaq will accept the Company’s compliance plan or that the Company will be able to regain compliance with the Rule.
Forward Looking Statements
This Current Report contains forward-looking statements that involve risks and uncertainties intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of current or historical fact contained in this Current Report, including statements regarding the Company’s expected timeline for compliance with the Nasdaq’s Corporate Governance Rules, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. The Company has based these forward-looking statements on the current expectations about future events held by management. While the Company believes these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company’s control. The Company’s actual future results may differ materially from those discussed here for various reasons. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this Current Report are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC.
By:/s/ Paul J. Sekhri
Name:Paul J. Sekhri
Title:President and Chief Executive Officer
Dated: June 26, 2023

 EX-101.SCH 2 vtvt-20230621.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vtvt-20230621_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 4 vtvt-20230621_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 21, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 21, 2023
Entity Registrant Name vTv Therapeutics Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37524
Entity Tax Identification Number 47-3916571
Entity Address, Address Line One 3980 Premier Drive, Suite 310
Entity Address, City or Town High Point
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27265
City Area Code 336
Local Phone Number 841-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per share
Trading Symbol VTVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001641489
XML 6 vtvt-20230621_htm.xml IDEA: XBRL DOCUMENT 0001641489 2023-06-21 2023-06-21 false 0001641489 NASDAQ 8-K 2023-06-21 vTv Therapeutics Inc. DE 001-37524 47-3916571 3980 Premier Drive, Suite 310 High Point NC 27265 336 841-0300 false false false false Class A common stock, par value $0.01 per share VTVT NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G M%C:^?VZH: MTE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P M9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<' M)O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:- MY&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_ M4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L# M!!0 ( ^#VE8D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2 MO6H0DBBZ0=@S9)[NF:*'3^ M 5!+ P04 " /@]I699!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S M72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2 M%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-; M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKB MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_' MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'" M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( ^#VE8'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ M#X/:5H\^)SKN *P( !$ ( !KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @ #X/:5IE&PO=V]R:W-H965T&UL4$L! A0#% @ #X/:5I^@&_"Q @ X@P T M ( !F0P 'AL+W-T>6QE$ >&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ #X/:5B0>FZ*M ^ $ !H ( ! MOA$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !HQ( %M#;VYT96YT7U1Y<&5S ;72YX;6Q02P4& D "0 ^ @ [1, end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - vtvt-20230621.htm 4 vtvt-20230621.htm vtvt-20230621.xsd vtvt-20230621_lab.xml vtvt-20230621_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vtvt-20230621.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "vtvt-20230621.htm" ] }, "labelLink": { "local": [ "vtvt-20230621_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20230621_pre.xml" ] }, "schema": { "local": [ "vtvt-20230621.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20230621", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20230621.htm", "contextRef": "i6497180fc87b4e4bb01ca6ecf374220a_D20230621-20230621", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vtvtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20230621.htm", "contextRef": "i6497180fc87b4e4bb01ca6ecf374220a_D20230621-20230621", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001641489-23-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-23-000043-xbrl.zip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end